Alzheimer’s Drugs Market

Published By: Zion Market Research
Alzheimer’s Drugs Market by Drug Class (Cholinergic, Memantine and Combined Drug), by Distribution Channel
(Hospital Pharmacy, Retail Pharmacy and Online Sales), and by Region: Global Industry Perspective, Comprehensive
Analysis and Forecast, 2014 - 2022
Contact Us:
4283, Express Lane, Suite 634-143,
Sarasota, Florida 34249, United States
Tel: +1-386-310-3803 GMT
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
sales@zionmarketresearch.com

Alzheimer’s Drugs Market
Zion Market Research has published a new report titled “Alzheimer’s Drugs Market by Drug Class
(Cholinergic, Memantine, and Combined Drug), by Distribution Channel (Hospital Pharmacy, Retail
Pharmacy, and Online Sales), and by Region: Global Industry Perspective, Comprehensive Analysis,
and Forecast, 2014 - 2022”. According to the report, global Alzheimer’s drugs market was valued at
approximately USD 3.42 billion in 2016 and is expected to generate revenue of around USD 5.09
billion by end of 2022, growing at a CAGR of around 8% between 2017 and 2022.
Alzheimer’s is a neurodegenerative, progressive disease of the brain, which leads to loss of memory
and cognitive functions. It also involves parts of the brain which control thought, memory, and
language and over time can seriously affect a person’s ability to carry out daily activities. Alzheimer's
is the most common form of dementia, and it accounts for 60-80% of dementia cases. As Alzheimer's
is a progressive disease, in which symptoms of the disease gradually worsen over a number of years.
This disease has no current cure, but treatments for symptoms are available and research continues.
Request For Free Sample Report: https://goo.gl/4eQPP1
Global Alzheimer’s drugs are primarily driven by worldwide growing prevalence of Alzheimer’s
disease, increasing awareness about the treatment of Alzheimer’s disease. Other major driving factors
of Alzheimer’s drugs market are, several neurodegenerative diseases have become increasingly
prevalent in the developing countries such as the U.S. in the past few years. This is leading to a

Alzheimer’s Drugs Market
steady support from the government to develop a drug for treatment. However, high prices of the
advanced drugs can create restraints to the Alzheimer’s drugs market in the developing countries like
the Asia Pacific. Additionally, awareness about Alzheimer’s disease remains restricted, which has
resulted in unstable healthcare systems and uncooperative research infrastructure in developing
countries may limit the growth of the market.
Request Report TOC (Table of Contents) @ https://goo.gl/TLjdPE
(Purchase Single User License at $4199)
The Alzheimer’s Drugs are segmented on the basis of drug class including cholinergic, memantine
and combined drug. On the basis of the distribution channel, Alzheimer’s drugs are segmented as
hospital pharmacy, retail pharmacy, and online sales. Of these, memantine is likely to remain the
leading contributor to the global Alzheimer's drugs market in the near future; it is primarily due to the
lack of effective drug classes in several developing regions. Combined drug treatment is also likely to
remain a major contributor to the global Alzheimer's drugs market in the coming years due to the
growing recognition of its efficacy and rising availability in developed countries.
Browse the full report at: https://goo.gl/CfzrTh
North America, Europe, Asia-Pacific, Latin America and Middle East & Africa are key regional
segments of global Alzheimer’s drugs. North America is projected to dominate the global
Alzheimer’s drugs market. Owing to rising prevalence of disease across this region and presence of
global players which has made distribution easier in the region are the key factors responsible for the

Alzheimer’s Drugs Market
large share of this regional segment. However, Europe also has an immense potential for expansion,
due to growing geriatric population. Asia Pacific is also expected to expand at a considerable high
rate, displaying a promising CAGR during the forecast period.
Some of the key players in Alzheimer’s Drugs are Ono Pharmaceutical, Johnson & Johnson, Daiichi
Sankyo Company Limited, H Lundbeck A/S, Eisai Co Ltd., and among others.
This report segments the global Alzheimer’s Drugs is as follows:
Global Alzheimer’s Drugs: by Drug Class
Cholinergic
Memantine
Combined Drug
Global Alzheimer’s Drugs: by Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Sales
Global Alzheimer’s Drugs: By Region
North America

Alzheimer’s Drugs Market
o U.S.
Europe
o UK
o France
o Germany
Asia Pacific
o China
o Japan
o India
Latin America
o Brazil
The Middle East and Africa
Table of Contents
Chapter 1. Introduction
o 1.1. Report description and scope
o 1.2. Research scope
o 1.3. Research methodology
• 1.3.1. Market research process
• 1.3.2. Market research methodology
Chapter 2. Executive Summary
o 2.1. Global Alzheimer’s drugs market, 2014 – 2022 (USD Billion)
o 2.2. Global Alzheimer’s drugs market: Snapshot
Chapter 3. Alzheimer’s Drugs Market Dynamics

Alzheimer’s Drugs Market
o
o
o
o
o
o
3.1. Introduction
3.2. Market drivers
• 3.2.1. Global Alzheimer’s drugs market drivers: Impact analysis
• 3.2.2. Growing occurrence of diseases in developed western countries
• 3.2.3. Steady government support for Alzheimer’s drug development, growing awareness
about treatment of Alzheimer’s disease
3.3. Market restraints
• 3.3.1. High prices of advanced drugs
• 3.3.2. Awareness about Alzheimer’s disease remains limited in developing countries like
Southeast Asia
3.4. Opportunities
• 3.4.1. Growing support for mental care infrastructure from governments in several developing
Asia Pacific countries is thus likely to drive the Alzheimer's drugs market in he region in the
coming years.
3.5. Porter’s five forces analysis
• 3.5.1. Bargaining power of suppliers
• 3.5.2. Bargaining power of buyers
• 3.5.3. Threat from new entrants
• 3.5.4. Threat from new substitutes
• 3.5.5. Degree of competition
3.6. Market attractiveness analysis
• 3.6.1. Market attractiveness analysis, by Drug Class
• 3.6.2. Market attractiveness analysis, by Distribution Channel
• 3.6.3. Market attractiveness analysis, by Regional Segment

Alzheimer’s Drugs Market
Chapter 4. Global Alzheimer’s Drugs Market – Competitive Landscape
o 4.1. Company Market Share Analysis
• 4.1.1. Global Alzheimer’s drugs market: company market share, 2015
o 4.2. Strategic Development
• 4.2.1. Acquisitions & Mergers
• 4.2.2. New Drug Class Launch
• 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
• 4.2.4. Research and Development, Regional Expansion
Chapter 5. Global Alzheimer’s Drugs Market – Drug Class Segment Analysis
o 5.1. Global Alzheimer’s drugs market: Drug Class overview
• 5.1.1. Global Alzheimer’s drugs market revenue share, by Drug Class, 2014 and 2022(USD
Billion)
o 5.2. Cholinergic
• 5.2.1. Global Cholinergic drugs market, 2014 – 2022(USD Billion)
o 5.3. Memantine
• 5.3.1. Global Memantine drugs market, 2014 – 2022(USD Billion)
o 5.4. Combined Drug
• 5.4.1. Global Combined drugs market, 2014 – 2022(USD Billion)

Alzheimer’s Drugs Market
Browse the full "Alzheimer’s Drugs Market by Drug Class (Cholinergic,
Memantine, and Combined Drug), by Distribution Channel (Hospital Pharmacy, Retail
Pharmacy, and Online Sales), and by Region: Global Industry Perspective, Comprehensive
Analysis, and Forecast, 2014 - 2022" report
at https://www.zionmarketresearch.com/report/alzheimers-drugs-market
Zion Market Research
Address: 4283, Express Lane, Suite 634-143, Sarasota, Florida 34249, United States
Tel: +1-386-310-3803 GMT
+49-322 210 92714 Tel: +1-855-465-4651 (US/CAN TOLL FREE)
Email: sales@zionmarketresearch.comWeb:www.zionmarketresearch.com